2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2303

Clinical Characteristics Of Rheumatoid Factor-Positive Or Negative Subsets Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis
Abstract Number: 684

Clinical Characteristics Of Scleroderma Patients With Calcinosis In a Single-Center Cohort
Abstract Number: 1560

Clinical Characterization Of Anti-CCP+Ve Systemic Lupus Erythematosus Patients
Abstract Number: 412

Clinical Characterization Of Extensive Interstitial Lung Disease In Rheumatoid Arthritis Patients
Abstract Number: 1584

Clinical Correlates Of Chronic Isolated Thrombocytopenia In Patients With Systemic Lupus Erythematosus
Abstract Number: 18

Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Abstract Number: 472

Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Abstract Number: 8

Clinical Evaluation Of Two Anti-Beta₂glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Abstract Number: 2062

Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo-1 Autoantibody
Abstract Number: 2617

Clinical Features Of 127 Patients With Behcet’s Disease In Japan
Abstract Number: 1679

Clinical Implications Of Antiphospholipid Antibodies In Takayasu’s Arteritis
Abstract Number: 1305

Clinical Joint Involvement Is Decisive For Radiographic Progression
Abstract Number: 2486

Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers
Abstract Number: 344

Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Abstract Number: 1061

Clinical Phenotypes and Disease Burden Of Discoid Lupus Erythematosus In a Sample Of Systemic Lupus Erythematosus Patients In The Southeastern United States

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].